Edition:
India

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

255.30INR
6 Dec 2019
Change (% chg)

Rs-2.35 (-0.91%)
Prev Close
Rs257.65
Open
Rs258.00
Day's High
Rs260.95
Day's Low
Rs253.00
Volume
1,246,246
Avg. Vol
1,566,197
52-wk High
Rs359.75
52-wk Low
Rs206.50

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Says Inspection By US FDA Of Co's API Manufacturing Facility Located At Dabhasa, Gujarat
Friday, 6 Dec 2019 

Dec 6 (Reuters) - Cadila Healthcare Ltd ::CADILA HEALTHCARE LTD SAYS INSPECTION BY US FDA OF COMPANY''S API MANUFACTURING FACILITY LOCATED AT DABHASA, GUJARAT.CADILA HEALTHCARE - CO RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) WHICH STATED THAT CLASSIFICATION OF FACILITY IS "NO ACTION INDICATED (NAI)"..  Full Article

Cadila Healthcare Says Zydus Announces Regulatory Filing Of Saroglitazar Magnesium
Thursday, 5 Dec 2019 

Dec 5 (Reuters) - Cadila Healthcare Ltd ::ZYDUS ANNOUNCES REGULATORY FILING OF SAROGLITAZAR MAGNESIUM FOR TREATMENT OF NASH WITH DCGI.  Full Article

Cadila Healthcare Says Zydus Announces Second Phase 3 Trial Of Desidustat
Monday, 18 Nov 2019 

Nov 18 (Reuters) - Cadila Healthcare Ltd ::ZYDUS ANNOUNCES SECOND PHASE 3 TRIAL OF DESIDUSTAT.  Full Article

Cadila Healthcare Buys 15% Stake In Zydus Technologies
Wednesday, 13 Nov 2019 

Nov 13 (Reuters) - Cadila Healthcare Ltd ::ACQUIRED 15% EQUITY SHARE CAPITAL OF ZYDUS TECHNOLOGIES.ALSO ACQUIRED 15% COMMON STOCK OF ZYDUS NOVELTECH INC., USA.  Full Article

Cadila Healthcare Says Zydus Gets Final USFDA Nod For Cisatracurium Besylate Injection USP
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR CISATRACURIUM BESYLATE INJECTION USP.DRUG WILL BE MANUFACTURED AT UNIT LIVA PHARMACEUTICALS.  Full Article

Cadila Healthcare Gets Warning Letter Issued By US FDA Relating To Moraiya Formulation Facility
Monday, 4 Nov 2019 

Nov 4 (Reuters) - Cadila Healthcare Ltd ::. - WARNING LETTER - US FDA.SAYS COMPANY HAS RECEIVED A WARNING LETTER ISSUED BY US FDA RELATING TO ITS MORAIYA FORMULATION FACILITY..WARNING LETTER RELATING TO ITS MORAIYA FORMULATION FACILITY.WILL CONTINUE TO TAKE NECESSARY STEPS TO ENSURE THAT US FDA IS FULLY SATISFIED WITH REMEDIATION OF ABOVE FACILITY.CONFIDENT OF RESPONDING TO US FDA TO ADDRESS THE OBSERVATIONS WITHIN THE STATUTORY TIME.CADILA HEALTHCARE -WARNING LETTER DOES NOT AFFECT EXISTING BUSINESS OF CO IN US AND THE EXISTING PRODUCT SUPPLIES FROM MORAIYA FACILITY TO CONTINUE..  Full Article

Cadila Healthcare Says API Manufacturing Facility At Dabhasa Completes U.S. FDA Inspection
Friday, 11 Oct 2019 

Oct 11 (Reuters) - Cadila Healthcare Ltd ::CADILA HEALTHCARE LTD - API MANUFACTURING FACILITY AT DABHASA SUCCESSFULLY COMPLETES USFDA INSPECTION.  Full Article

Cadila Gets US FDA's 'NAI' Classification For Ankleshwar Plant
Monday, 23 Sep 2019 

Sept 23 (Reuters) - Cadila Healthcare Ltd ::SAYS US FDA EIR REPORT CLASSIFIED ANKLESHWAR FACILITY AS 'NO ACTION INDICATED'.SHARES RISE 2% AFTER US FDA SAYS 'NO ACTION INDICATED' FOLLOWING INSPECTION AT ANKLESHWAR PLANT.  Full Article

Cadila Healthcare Says U.S. FDA Classifies Co's Moraiya Facility As OAI
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Cadila Healthcare Ltd ::GETS LETTER FROM U.S. FDA CLASSIFYING INSPECTION AT CO'S MORAIYA FACILITY AS 'OFFICIAL ACTION INDICATED' (OAI).CLASSIFICATION WILL NOT HAVE ANY IMPACT ON CURRENT SUPPLIES OR REVENUES OF FACILITY.IN PROCESS OF SENDING FURTHER UPDATES OF ITS CORRECTIVE ACTIONS TO U.S. FDA.  Full Article

Cadila Healthcare Says U.S. FDA Inspects Co's API Manufacturing Facility At Ankleshwar
Friday, 26 Jul 2019 

July 26 (Reuters) - Cadila Healthcare Ltd ::SAYS USFDA INSPECTED CO'S API MANUFACTURING FACILITY LOCATED AT ANKLESHWAR.SAYS AT END OF INSPECTION, NO OBSERVATION (483) IS ISSUED.  Full Article